Wells Fargo & Company Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price objective lifted by research analysts at Wells Fargo & Company from $350.00 to $360.00 in a research note issued to investors on Friday,MarketScreener reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 10.66% from the stock’s previous close.

PODD has been the subject of several other reports. Royal Bank Of Canada lifted their target price on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a report on Friday, October 10th. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Barclays lifted their price target on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Rothschild & Co Redburn increased their price target on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $367.74.

Insulet Stock Up 0.6%

Shares of PODD stock traded up $1.93 during mid-day trading on Friday, hitting $325.33. 68,467 shares of the stock traded hands, compared to its average volume of 718,270. The stock’s fifty day moving average is $325.46 and its two-hundred day moving average is $308.84. The stock has a market cap of $22.90 billion, a P/E ratio of 99.11, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet has a 52-week low of $230.05 and a 52-week high of $353.50.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same period in the prior year, the firm earned $1.08 EPS. The firm’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts predict that Insulet will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. True Wealth Design LLC lifted its position in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Insulet in the 1st quarter valued at $26,000. Larson Financial Group LLC raised its stake in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares in the last quarter. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the last quarter. Finally, SouthState Corp lifted its position in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.